MX2020005155A - Composiciones y metodos de uso para tratar inflamacion aberrante en glandulas secretoras perioculares o en la superficie ocular. - Google Patents
Composiciones y metodos de uso para tratar inflamacion aberrante en glandulas secretoras perioculares o en la superficie ocular.Info
- Publication number
- MX2020005155A MX2020005155A MX2020005155A MX2020005155A MX2020005155A MX 2020005155 A MX2020005155 A MX 2020005155A MX 2020005155 A MX2020005155 A MX 2020005155A MX 2020005155 A MX2020005155 A MX 2020005155A MX 2020005155 A MX2020005155 A MX 2020005155A
- Authority
- MX
- Mexico
- Prior art keywords
- ocular
- methods
- peri
- compositions
- ocular surface
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 210000004907 gland Anatomy 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000001594 aberrant effect Effects 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000003248 secreting effect Effects 0.000 title 1
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 210000004175 meibomian gland Anatomy 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000037317 transdermal delivery Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Se proporciona en la presente composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva de un compuesto lipofílico y un portador farmacéuticamente aceptable adaptado para el suministro transdérmico periocular del compuesto lipofílico a una o más glándulas periorbitales y/o los tejidos de superficie ocular de un sujeto. Además se proporcionan en métodos para utilizar tales composiciones farmacéuticas para proporcionar alivio de uno o más signos o síntomas de una enfermedad ocular, métodos para utilizar una o más glándulas Meibomianas (y el meibum en el mismo) como un sistema de suministro del fármaco para compuesto lipofílico (por ejemplo, un esteroide) a la superficie ocular, y kits relacionados con los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762589493P | 2017-11-21 | 2017-11-21 | |
PCT/US2018/062298 WO2019104207A2 (en) | 2017-11-21 | 2018-11-21 | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005155A true MX2020005155A (es) | 2020-08-20 |
Family
ID=64664492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005155A MX2020005155A (es) | 2017-11-21 | 2018-11-21 | Composiciones y metodos de uso para tratar inflamacion aberrante en glandulas secretoras perioculares o en la superficie ocular. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230372360A1 (es) |
EP (1) | EP3713544A2 (es) |
JP (2) | JP7440419B2 (es) |
KR (1) | KR20200089703A (es) |
CN (1) | CN111372564A (es) |
AU (1) | AU2018372185A1 (es) |
BR (1) | BR112020008046A2 (es) |
CA (1) | CA3080166A1 (es) |
CL (1) | CL2020001339A1 (es) |
IL (1) | IL274810A (es) |
MA (1) | MA49912A (es) |
MX (1) | MX2020005155A (es) |
RU (1) | RU2020116802A (es) |
SG (1) | SG11202004307UA (es) |
WO (1) | WO2019104207A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102017220539A1 (de) | 2017-11-17 | 2019-05-23 | Zf Friedrichshafen Ag | Verfahren zum Betreiben eines Systems aus einem landwirtschaftlichen Arbeitsfahrzeug und zumindest einem an diesem angeordneten Arbeitsgerät |
EP4247367A1 (en) | 2020-11-23 | 2023-09-27 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6659985B2 (en) * | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
JP2010520210A (ja) * | 2007-02-28 | 2010-06-10 | アーシエックス セラピューティックス, インコーポレイテッド | マイボーム腺分泌を正常化するための方法および組成物 |
US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
US8900626B2 (en) * | 2011-06-20 | 2014-12-02 | Senju Usa, Inc. | Transdermal drug delivery system and method of using the same |
IN2014MN01571A (es) * | 2012-02-10 | 2015-05-15 | Taiwan Liposome Co Ltd | |
CN104224709B (zh) * | 2013-06-09 | 2017-06-23 | 宁波润增医疗科技有限公司 | 一种基于水包油型乳液且能使药物高效释放的药物制剂 |
ES2712849T3 (es) * | 2014-12-12 | 2019-05-16 | Alfa Intes Ind Terapeutica Splendore S R L | Composiciones oftálmicas para su uso en el tratamiento del síndrome del ojo seco |
MX2017010544A (es) * | 2015-02-24 | 2018-06-18 | Univ Illinois | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. |
AR104177A1 (es) * | 2015-04-03 | 2017-07-05 | Santen Pharmaceutical Co Ltd | Sistema para la administración de fármacos en la glándula lagrimal |
AU2017264697A1 (en) * | 2016-05-09 | 2018-11-22 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
-
2018
- 2018-11-21 CA CA3080166A patent/CA3080166A1/en active Pending
- 2018-11-21 MX MX2020005155A patent/MX2020005155A/es unknown
- 2018-11-21 WO PCT/US2018/062298 patent/WO2019104207A2/en unknown
- 2018-11-21 JP JP2020545082A patent/JP7440419B2/ja active Active
- 2018-11-21 AU AU2018372185A patent/AU2018372185A1/en active Pending
- 2018-11-21 EP EP18816410.7A patent/EP3713544A2/en active Pending
- 2018-11-21 KR KR1020207017401A patent/KR20200089703A/ko not_active Application Discontinuation
- 2018-11-21 RU RU2020116802A patent/RU2020116802A/ru unknown
- 2018-11-21 BR BR112020008046-2A patent/BR112020008046A2/pt unknown
- 2018-11-21 MA MA049912A patent/MA49912A/fr unknown
- 2018-11-21 CN CN201880074872.9A patent/CN111372564A/zh active Pending
- 2018-11-21 SG SG11202004307UA patent/SG11202004307UA/en unknown
-
2020
- 2020-05-20 CL CL2020001339A patent/CL2020001339A1/es unknown
- 2020-05-20 IL IL274810A patent/IL274810A/en unknown
-
2023
- 2023-08-01 US US18/229,105 patent/US20230372360A1/en active Pending
-
2024
- 2024-02-15 JP JP2024021166A patent/JP2024056898A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7440419B2 (ja) | 2024-02-28 |
CN111372564A (zh) | 2020-07-03 |
BR112020008046A2 (pt) | 2020-10-27 |
AU2018372185A1 (en) | 2020-05-14 |
US20230372360A1 (en) | 2023-11-23 |
SG11202004307UA (en) | 2020-06-29 |
RU2020116802A (ru) | 2021-11-22 |
JP2024056898A (ja) | 2024-04-23 |
CA3080166A1 (en) | 2019-05-31 |
CL2020001339A1 (es) | 2020-10-23 |
KR20200089703A (ko) | 2020-07-27 |
WO2019104207A3 (en) | 2019-07-04 |
WO2019104207A2 (en) | 2019-05-31 |
MA49912A (fr) | 2020-06-24 |
EP3713544A2 (en) | 2020-09-30 |
IL274810A (en) | 2020-07-30 |
JP2021504451A (ja) | 2021-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016219611A1 (en) | Compositions comprising mixtures of semifluorinated alkanes | |
BR112020015688A8 (pt) | Formulações tópicas que compreendem tofacitinibe | |
AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
JP2017039771A5 (es) | ||
GT200000184A (es) | Composiciones para facilitar el crecimiento de la piel y metodos y articulos que la emplean. | |
RU2013118325A (ru) | Лечение рака молочной железы | |
ECSP14012676A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
MX2019003685A (es) | Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer. | |
UY32822A (es) | Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos | |
MX2020005155A (es) | Composiciones y metodos de uso para tratar inflamacion aberrante en glandulas secretoras perioculares o en la superficie ocular. | |
MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
WO2017091767A3 (en) | Drug formulations for cancer treatment | |
CO2019014671A2 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso | |
MX2017005163A (es) | Composiciones de liberación prolongada de onapristona y métodos. | |
MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
ZA201908404B (en) | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases |